A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder
Latest Information Update: 19 Oct 2023
At a glance
- Drugs Fremanezumab (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Acronyms UNITE
- Sponsors Teva Branded Pharmaceutical Products R&D
Most Recent Events
- 17 Oct 2023 According to Teva Pharmaceuticals media release, data from this study presented at the World Congress of Neurology in Montreal, Canada
- 17 Oct 2023 Results published in the Teva Pharmaceuticals Media Release
- 02 Oct 2023 Primary endpoint (Change From Baseline in Monthly Average Number of Migraine Days During the 12-Week DB Treatment Phase After the First Dose of Study Drug) has been met as per results published in the ClinicalTrials.gov Trial Registry